Clinical Trial Update: An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 open-label randomized neoadjuvant trial evaluating nivolumab plus chemotherapy with or without sub-ablative SBRT in patients with resectable s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• OPDIVO (nivolumab)

Snippet

Sponsor: Montefiore Medical Center | Conditions: Resectable Stage IIA to IIIB Non-small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING